CERE News and Press, Ceres Inc. From 06/29/21

Shares of Cerevel Therapeutics Holdings (NASDAQ: CERE) are surging after the Pfizer (NYSE: PFE) spinoff reported topline results for an experimental new schizophrenia drug. Successful topline data make it look like Pfizer shouldn't have spun off a handful of neuroscience...

Gainers: BSQUARE Corporation (BSQR) +99%.Cerevel Therapeutics Holdings (CERE) +94%.Marin Software Incorporated (MRIN) +73%.Exela Technologies (XELA) +43%.Weidai (WEI) +39%.Infobird (IFBD) +36%.Powerbridge Technologies (PBTS) +31%.Auddia (AUUD) +23%.Amesite (AMST) +22%.Global Internet of Peopl...

Gainers: Cerevel Therapeutics CERE +113%, Avinger (AVGR) +22%, Translate Bio TBIO +14%, Orphazyme ORPH +11%, Regional Health Properties (RHE) +8%.Losers: DiaMedica Therapeutics DMAC -33%, MediWound MDWD -29%, ReShape Lifescience...

naphtalina/iStock via Getty Images Biggest. Order. Ever. United Airlines (UAL) made headlines Tuesday by announcing the largest aircraft purchase in the company's history. Jefferies (JEF) and Herman Miller (MLHR) both moved in pre-market trading after the release of earnings news. Cerevel The...

BSQUARE Corporation (BSQR) +77%.Exela Technologies (XELA) +59% after rollout of its Robotic Process Automation platform.Cerevel Therapeutics Holdings (CERE) +40% after positive results from its early-stage trial of CVL-231.Auddia (AUUD) +37% after launching its flagship app.Ver...

Cerevel Therapeutics (CERE) shares jump more than 30% during premarket trading after the company posted positive results from its early-stage trial of CVL-231, a novel muscarinic M4-selective Positive Allosteric Modulator ((PAM)), in adult patients with schizophrenia.Both ...

Both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks and were overall well-tolerated compared with placebo 30 mg of CVL-231 once-daily improved PANSS total score at 6 weeks by 12.7 points compared wi...

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designat...

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2021 Q1 - Results - Earnings Call Presentation

Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2021 Results Earnings Conference Call May 17, 2021, 08:00 AM ET Company Participants Matt Calistri - Vice President, Investor Relations Tony Coles - Chairperson & Chief Executive Officer Abraham Ceesay - President Ray Sanchez - Chief Medical O...